StreetAlpha.app
Home › Stocks › SPRB

Spruce Biosciences, Inc. (SPRB)

$40.49
▼ −4.17%
LAST CLOSE · NOV 17

Spruce Biosciences develops therapies for neurological disorders, led by an enzyme replacement therapy for a rare genetic brain disease. It last closed at $40.49 on Nov 17, down 4.17% on the day.

AI Auto Pilots
Is SPRB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$67.1M
EPS (diluted)
−$33.29
Valuation
Market cap
$116.4M
2.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$87.7M
At Sep 30
Debt
$19.5M
At Sep 30
Shareholder equity
$66.3M
Shares outstanding
2.9M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $10.1M$10.1MFY2023FY2024: $4.9M$4.9MFY2024FY2025: $0$0FY2025

From SPRB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated SPRB in the past 90 days, not enough for a consensus
Average 12-month target
$149.00
▲ 268.0% upside

Based on 1 analyst who set a price target on SPRB in the past 90 days. The average target is $149.00, with a high of $149.00 and a low of $149.00, compared with the last close of $40.49.

Low $149.00Avg $149.00High $149.00
Blue marker: last close $40.49
Highest target$149.00
Average target$149.00
Lowest target$149.00
Latest rating changes
Lake StreetInitiated
Sep 17Buy$149
GuggenheimTarget lowered
Aug 17Buy$123 → $104
CitizensMaintained
Aug 13Buy$144
B. Riley SecuritiesInitiated
Jul 13Buy$160
GuggenheimInitiated
Jun 16Buy$123
DateFirmActionRatingPrice target
Sep 17Lake StreetInitiatedBuy$149
Aug 17GuggenheimTarget loweredBuy$123 → $104
Aug 13CitizensMaintainedBuy$144
Jul 13B. Riley SecuritiesInitiatedBuy$160
Jun 16GuggenheimInitiatedBuy$123
Loading…

Technical Analysis

SPRB · as of the Nov 17 close · updated after every close
Downtrend

The stock is 11% below its 20 day and 15% below its 50 day average. It is 33% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Jul 28) at $40.33, and the nearest resistance the Pivot at $40.76.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 8.3%/day
Key levels
$127.9052 week high+215.9%
$53.70200 day average+32.6%
$48.48100 day average+19.7%
$46.5450 day average+14.9%
$45.51Swing high (Jul 27)+12.4%
$44.9020 day average+10.9%
$41.54Pivot R1+2.6%
$40.76Pivot+0.7%
$40.49Last close
$40.33Swing low (Jul 28)−0.4%
$39.71Pivot S1−1.9%
$38.0652 week low−6.0%
Indicators
RSI (14)40.87Middle of its rangeNeutral
MACD-0.80Below its signal lineBearish
Stochastic12.6Near the bottom of its rangeOversold
ADX (14)15.2No clear trend
Williams %R-95.6Oversold below −80, overbought above −20Oversold
CCI (20)-188.0Oversold below −100, overbought above 100Oversold
Rate of change−5.4%Change over 10 sessionsBearish
ATR (14)$3.38Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRB

What happened before

See how SPRB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SPRB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SPRB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SPRB in the last 90 days.

Loading…

See today’s whale options flow across the market →

SPRB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲35 buying vs 24 selling
  • ▼Held by funds -2.2 pts
  • ▲Funds holding +7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7164+10.9%
In funds' top 10110.0%
Held by funds72.6%74.8%−2.2 pts
New / increased12 / 2336 / 16−32.7%
Reduced / sold out18 / 63 / 4+242.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRB is in one of them and how their past SPRB trades turned out.

SPRB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRB in an article yet. Here's the latest on the wider market.

About Spruce Biosciences

Spruce Biosciences is a biopharmaceutical company that develops therapies for neurological disorders. Its lead product candidate, TA-ERT, is an enzyme replacement therapy under development for MPS IIIB, a rare genetic disease that causes progressive brain damage and has no approved treatments. The therapy is designed to be delivered directly into the central nervous system, and its intended customers are patients with the disease and the clinicians who treat them. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA